Celgene Patent on Revlimid to Be Reviewed on Bass Challenge
This article is for subscribers only.
Hedge-fund manager Kyle Bass has persuaded a federal agency that a Celgene Corp. patent on the blood cancer drug Revlimid may be invalid.
The U.S. Patent and Trademark Office on Tuesday said Bass’s Coalition for Affordable Drugs has a “reasonable likelihood” of success in his challenge to a patent that expires in 2018. A final decision in the case will come in about a year.